Afyx Therapeutics A/S: Financial statements 2020
CVR: 38793594
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
Afyx Therapeutics A/S (CVR 38793594) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -585,934 and a net result of DKK -1,506,650 compared with DKK -1,569,660 the year before. Equity in the 2020 report amounted to DKK 4,696,027. The solvency ratio was 77%. The company had 2 employees in the financial year.
- Gross Profit
- DKK -585,934
- Profit/Loss
- DKK -1,506,650
- Equity
- DKK 4,696,027
- Total Assets
- DKK 6,095,001
- Employees
- 2
Official annual report
How creditworthy is Afyx Therapeutics A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
Afyx Therapeutics A/S has published its annual report for 2019. Gross profit came to DKK -1,134,301, and the net result was DKK -1,569,660.
About Afyx Therapeutics A/S
Afyx Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2017. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Inphena A/S and Inphena ApS. The management consists of Claus Juan Møller-San Pedro. The board consists of Ole Baadsgaard (chair), Claus Juan Møller-San Pedro, Pia Leah Møller-San Pedro and Søren Mohrsen Kjær. The company is owned by Afyx Capital ApS. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK 23,138,320 and a net result of DKK 1,518,132 compared with DKK -3,810,585 the year before. Equity in the 2025 report amounted to DKK 36,178,254.
